blood component therapy

blood component therapy

transfusion of one or more of the components of whole blood to treat a specific deficiency.
The therapeutic use of specific portions—components—of blood—e.g., factor VIII concentrates, packed red cells, or platelets—rather than whole blood

blood component therapy

Component therapy The therapeutic use of specific portions–components of blood–eg, factor VIII concentrates, packed red cells, or platelets rather than whole blood

blood component therapy

Transfusion of one or more of the components of whole blood. The blood components may have been taken from the patient previously (autologous transfusion) or donated by someone else (homologous transfusion). Except in the case of acute hemorrhage, the transfusion of whole blood is rarely needed. Use of a component rather than whole blood permits several patients to benefit from a single blood donation. Blood components used in clinical medicine include packed red blood cells (RBCs); leukocyte-poor RBCs; frozen glycerolized RBCs; thawed deglycerolized RBCs; washed RBCs; whole blood; heparinized whole blood; granulocytes; platelets; and plasma and plasma fractions. The latter include antihemophilic factor (Factor VIII), prothrombin complex (Factors VII, IX, and X), gamma globulin, and albumin.

Patient care

Irradiation of blood by gamma rays (gamma irradiation) incapacitates donor lymphocytes in whole blood, RBCs, platelets, or granulocytes. These lymphocytes are blocked from proliferating in response to foreign antigens, esp. those in the bone marrow, of immunocompromised recipients, causing transfusion-associated graft-versus-host disease. In patients who are not immunocompromised, the donor white blood cells (WBCs) are destroyed. Irradiated blood is given to patients who are donating or receiving bone marrow transplants or who have hematological or lymphatic cancers. In addition, blood used for intrauterine or neonatal exchange transfusions and blood donated by a biological relative also is irradiated.

Washing blood (RBCs, platelets) in 0.9% sodium chloride removes most, but not all, of the antibodies that could trigger an adverse reaction, esp. in patients with a history of hypersensitivity reactions to blood transfusions, even when given antihistamine prophylaxis. Washed RBCs must be given within 24 hours because the risk of bacterial contamination is increased when the saline is injected into the bag of RBCs.

Use of leukocyte-poor blood reduces the risk of unwanted responses to WBCs (leukocytes), antibodies, and cytokines by the recipient. WBCs can be eliminated by using special filters in the intravenous line or through aphoresis. The process is used for patients with a history of allergic reactions to blood products or those expected to require multiple transfusions. It also prevents transmission of cytomegalovirus (CMV) to immunocompromised patients.

Screening blood for CMV and RBC antigens helps to identify CMV-negative blood, which is needed for high-risk patients. More than half of persons over 35 years of age have been infected with CMV. However, this screened blood is beneficial for premature infants; infants under age 4 weeks; recipients of intrauterine transfusion regardless of the mother’s CMV status; any patient who requires a bone marrow or organ donor transplant if the marrow or organ donor also is CMV-negative; and CMV-negative patients who are potential transplant candidates, pregnant, about to undergo splenectomy, or have AIDS/HIV or congenital immune deficiency.table; blood transfusion;

Abbreviations: dL=deciliter; INR=international normalized ratio; mL=milliliter
ComponentWhen it is usedApproximate volume (in mL) infused or typical preparationStorage/viabilityExpected outcome
Packed red blood cellsWhen needed to restore the oxygen-carrying capacity of the blood of the patient470Refrigerated or frozen; may last as long as 42 daysAn increase in hemoglobin of 1 g/dL
PlateletsIn severely thrombocytopenic patients, e.g., < 40,000/dL in hemorrhaging patients, or < 10,000, in patients who are not yet bleeding“Five-pack” (i.e., a pooled concentrate from five donors); single-donor apheresis packStored at room temperature (72° F); needs constant agitation; may last 5 daysAn increase in platelet counts of > 20,000/dL
Fresh-frozen plasma (FFP)To replace missing coagulation factors225Must be frozen within 6 hours of donation; useful for up to a yearImprovement in prothrombin time/INR
CryoprecipitateTo supply blood components; esp., fibrinogen, Factors VIII and XIII, fibronectin, and von Willebrand FactorPrepared from the insoluble proteins that remain when FFP is thawed for use. Ten-donor pack usually usedCan be refrozen and stored after use of FFP; usually useful for 28 daysIncrease in fibrinogen level by 2-5 mg
References in periodicals archive ?
Additional chapters address imaging, anesthesia, fluid and blood component therapy administration, procedures, wound management, universal/standard precautions, and administrative aspects like professionalism, communication and interpersonal issues, research, and nursing.
Iftikhar Ahmed, Director Ojha DUHS and Haematological Manifestations and Role of Blood Component Therapy by Prof.
2) American Society of Anesthesiologists, "Practice guidelines for blood component therapy: a report by the American Society of Anesthesiologists Task Force on Blood Component Therapy.
I like to refer them to an article published by The Task Force on Blood Component Therapy of the American Society of Anesthesiologists: Anesthesiology, which says: "The principal conclusions of the task force are that red blood cell transfusions should not be dictated by a single hemoglobin "trigger" but, instead, should be based on the patient's risks of developing complications of inadequate oxygenation.
We have significant worldwide experience in the development and commercialization of blood processing systems, blood component therapy, hospital based transfusion medicine and the regional blood center system," concluded Clibourn.
Marr will be responsible for new product development for both our Hospital/Acute Care and Blood Component Therapy Businesses.
The Company's systems address four important medical markets: surgical blood salvage, blood component therapy, automated red cell and plasma collection.
services for blood component therapy, blood-volume replacement and the
Baxter's Biotech Group is a global provider of products and services for blood component therapy, blood-volume replacement and the treatment of coagulation and immune disorders.
17, 1997--Haemonetics Corporation (NYSE:HAE) announced that it has acquired the direct distribution rights in the Taiwan market, for its surgical and blood component therapy products, from its distributor Weever Enterprises.
We feel that the Company's strategy to fund opportunities with our key blood bank customers in the service business will position the Company to take full advantage of its technology enhancements in the area of blood component therapy.